

2026 ISV ANNUAL CONGRESS			
ORAL PROGRAM			
MONDAY, 12 OCTOBER 2026			
08:00-10:00	REGISTRATION		Room
09:00-10:00	WELCOME COFFEE		Room
10:00-10:10	OPENING SESSION WELCOME BY ISV PRESIDENT: Manon Cox, NextWaveBio, USA CO-CHAIR REMARKS: Michael Schotsaert, Icahn School of Medicine at Mount Sinai, USA Lakshmi Krishnan, National Research Council (NRC), Canada Isabel Leroux-Roels, University of Ghent, Belgium		Room
10:10-10:55	STANLEY PLOTKIN LECTURE Yellow fever 17D live attenuated vaccine: A great vaccine but how does it work? Alan Barrett, The University of Texas Medical Branch (UTMB), USA		Room
10:55-11:45	PLENARY SESSION 1: Population Impact of Vaccination Session Chairs: TBC		Room
10:55-11:20	Clinical Data for the RSVpreF Vaccine in Older Adults, At-Risk Adults Aged 18-59, and Immunocompromised Adults Kumar Ilangovan, Pfizer Vaccine R & D, USA		
11:20-11:45	Rotavirus Vaccines: Where We Are and What’s Next Michelle Groome, University of Witwatersrand, South Africa		
11:45-12:15	KEYNOTE SPEAKER From Preclinical Insight to Clinical Evidence: Advancing the Next Generation of Pneumococcal Conjugate Vaccines Annaliesa Anderson, Pfizer, USA		Room
12:15-13:30	LUNCH		Room
12:30-13:30	SANOFI WORKSHOP		Room
13:30-15:05	PLENARY SESSION 2: Mucosal Vaccines Session Chairs: TBC		Room
13:30-13:55	New Insights Into Receptor Usage by Orthoflaviviruses Michael S. Diamond, Washington University School of Medicine, USA		
13:55-14:20	Adjuvants - The Tool to Obtain the Required Immune Responses in Vaccination Dennis Christensen, CRODA Pharma, Denmark		
14:20-14:35	Charting Mucosal Immune Responses to Influenza using Human Immune competent Organoids Martin Beukema, University Medical Center Groningen, The Netherlands		
14:35-14:50	Environmental drivers of oral typhoid vaccine responses in Uganda: dissecting rural–urban differences and the role of Schistosoma mansoni Bridgious Walusimbi, MRC/UVRI and LSHTM Uganda Research Unit, Uganda		
14:50-15:05	Inhaled aerosol vaccination with an adenoviral-vectored TB vaccine induces robust respiratory mucosal immunity in humans Sam Afkhami, McMaster University, Canada		
15:05-15:30	COFFEE BREAK		Room
15:30-17:35	CONCURRENT SESSION 1 (Room) Adjuvants Session Chairs: TBC	CONCURRENT SESSION 2 (Room) Vaccine Regulatory Science and Policy Session Chairs: TBC	CONCURRENT SESSION 3 (Room) “Bright Sparks” in Vaccinology PhD Student Session Session Chairs: TBC

15:30-15:55	Open-access Adjuvants for Prophylactic Human Vaccines Marcelle Van Mechelen, <i>Vaccine Formulation Institute, Switzerland</i>	Regulatory Acceptance of Immunological Biomarkers as Surrogate for Vaccine Efficacy – Ebola Zaire Vaccine Case Marie-Chantal Uwamwezi, <i>PATH, Belgium</i>	Cross-Reactive SARS-CoV-2 Antibodies in Pre-Pandemic Gambian Sera Exhibit Fc-Mediated Effector Activity Dawda Jobe, <i>MRC Unit The Gambia at LSHTM</i> <i>(15:30-15:40)</i> Seroepidemiology and serum bactericidal activity of IgG antibodies to Non Typhoidal Salmonella in healthy Children in Mukuru informal settlement in Kenya Schola Kamwethya, <i>Kenya Medical Research Institute, Kenya</i> <i>(15:40-15:50)</i> Switchover Break <i>(15:50-15:55)</i>
15:55-16:20	From Empirical Adjuvants to Programmable Immunity Nathalie Garcon, <i>n3j consulting, Belgium</i>	Beyond Efficacy — Economic Intelligence Across the Vaccine Development Pipeline Beate Sander, <i>University of Toronto, Canada</i>	The Effect of Malaria Intermittent Preventive Treatment on Vaccine Responses and SARS-CoV-2 Seroprevalence in Adolescents: Findings from a Randomised Controlled Trial Ludoviko Zirimenya, <i>MRC/UVRI & LSHTM Uganda Research Unit, Uganda</i> <i>(15:55-16:05)</i> APC-Mimetic Dendritic Cell-Derived Extracellular Vesicle Nanovaccine with STING Adjuvant Induces Long-Term Th1 Immunity and Immune Memory Against Dengue Virus Anindita Sengupta, <i>Indian Institute of Technology, India</i> <i>(16:05-16:15)</i> Switchover Break <i>(16:15-16:20)</i>
16:20-16:35	Antigen cross-presentation potentiating cancer vaccine adjuvant for T cell expansion and synergy with anti-PD-1 Giang Dang Chu, <i>Chonnam National University</i>	Primary Healthcare Surveillance and Vaccination Challenges During the 2025 Meningococcal Serogroup C Outbreak Response in Sokoto State, Northern Nigeria Ikechukwu Nnaji, <i>Nigeria Centre for Disease Control and Prevention (NCDC), Nigeria</i>	Induction of influenza-specific immunity in pigs using dissolvable microneedle patches to deliver an adenovirus-based vaccine Inés Co Rives, <i>University College Cork, Ireland</i> <i>Includes 5 minute Switchover Break</i>

16:35-16:50	Modulation of the bone marrow hematopoietic and immune cell landscape by vaccine adjuvants Eleanor Burgess, <i>Icahn School of Medicine</i>	Late Breaker Abstract Speaker + Affiliation	Systemic response and short-term functional changes following infection with Necator americanus third-stage infective larvae: Insights from a control human hookworm infection trial in Lambarene, Gabon Therese Vanessa Amana Bokagne, <i>Centre de Recherches Medicales de Lambarene, Gabonese Republic</i> <i>Includes 5 minute Switchover Break</i>	
16:50-17:05	Neutrophils are the dominant early responders to a potent liposomal vaccine adjuvant Lee Sims, <i>University of Oxford, United Kingdom</i>	Late Breaker Abstract Speaker + Affiliation	Intranasal protein-based vaccines protect against 2.3.4.4b H5N1 infection in young and old BALB/C mice Gabriel Laghlali, <i>Icahn School of Medicine at Mount Sinai, USA</i> <i>Includes 5 minute Switchover Break</i>	
17:05-17:20	Late Breaker Abstract Speaker + Affiliation	PANEL DISCUSSION	A simplified and sensitive assay for tracking virus-specific T cell responses in the nasal cavity during SARS-CoV-2 human challenge studies Previtha Dawn Sakthi Vale, <i>National University of Singapore, Singapore</i> <i>Includes 5 minute Switchover Break</i>	
17:20-17:35	Late Breaker Abstract Speaker + Affiliation		AI-Driven Infodemic Surveillance and Its Impact on COVID-19 Vaccine Uptake in Sub-Saharan Africa: A Multi-Country Study Angyiba Serge Andigema, <i>Department of Research, Bisons' Scholars, Douala, Cameroon</i>	
17:35-19:00	POSTER SESSION 1			Room
18:00-20:00	WELCOME RECEPTION			Room

2026 ISV ANNUAL CONGRESS				
ORAL PROGRAM				
TUESDAY, 13 OCTOBER 2026				
08:00-08:30	WELCOME COFFEE			Room
08:30-09:00	KEYNOTE SPEAKER Microbiota Control of Host Immunity Yasmine Belkaid, <i>Institut Pasteur, France</i>			Room
09:00-10:30	PLENARY SESSION 3: Vaccine Technology <i>Session Chairs: TBC</i>			Room
09:00-09:25	TITLE TBC Tarit Mukhopadhyay, <i>Merck, USA</i>			
09:25-09:50	Advancing Therapeutic Vaccines Through Clinically Validated LNP Delivery Technologies Xiangrong Song, <i>WestGene Biopharma, China</i>			
09:50-10:15	TITLE TBC Emilio Fumero, <i>Moderna, Spain</i>			
10:15-10:30	Safety, Reactogenicity and Immunogenicity of a Launch-iT Rabies Vaccine: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Study in Healthy Adults Joke Debruyne, <i>Astrivax Therapeutics, Belgium</i>			
10:30-11:00	KEYNOTE SPEAKER Entering the Vaccine Space During Uncertain Times Peter Marks, <i>Eli Lilly and Company, USA</i>			
11:00-11:30	COFFEE BREAK			Room
11:00-12:35	CONCURRENT SESSION 4 <i>(Room)</i> Immunotherapies <i>Session Chairs: TBC</i>	CONCURRENT SESSION 5 <i>(Room)</i> Vaccines for vector-borne diseases <i>Session Chairs: TBC</i>	CONCURRENT SESSION 6 <i>(Room)</i> “Bright Sparks” in Vaccinology ECR Session <i>Session Chairs: TBC</i>	
11:00-11:25	Unleashing our innate immune system as defense against disease Joost Kreijtz <i>Trained Therapeutix Discovery (TTxD), Netherlands</i>	From Efficacy to Impact: What We Can Learn About Dengue Vaccination From TAK-003, a Tetravalent Dengue Vaccine Liudmyla Budovska, <i>Takeda Pharmaceuticals International AG, Switzerland</i>	Effectiveness of PCV10 and PCV13 against invasive pneumonia disease in vietnamese children prior to national introduction: a matched case-control study Cong Hieu Truong, <i>Pasteur Institute in Ho Chi Minh City, Vietnam</i> <i>(11:00-11:10)</i> Age-specific immunity gaps and residual susceptibility to measles and rubella before and after the measles–rubella supplementary immunisation campaign in South India Ramya Madhavan, <i>Christian Medical College, India</i> <i>(11:10-11:20)</i> Switchover Break <i>(11:20-11:25)</i>	

11:25-11:50	Antibody effector functions in antiviral immunity Taia Wang <i>Stanford University School of Medicine, USA</i>	Controlled human infection studies to accelerate vaccine development Meta Roestenberg <i>Leiden University, Netherlands</i>	Antigen composition, not T-cell functionality, limits cross-reactivity to distant Coronaviruses after bivalent SARS2 Spike vaccination Ziyin Wang, <i>La Jolla Institute for Immunology, USA</i> <i>(11:25-11:35)</i> Implementation Effectiveness of a Community-Driven Vaccination Model at Boosting Immunization in Two Conflict Affected Health Districts of Cameroon: A Quasi-Experimental Study Derrick Nebangwa, <i>Community-Driven Vaccination Programme (CoVACC), Cameroon</i> <i>(11:35-11:45)</i> Switchover Break <i>(11:45-11:50)</i>	
11:50-12:05	In situ cancer immunotherapy with modified MVdeltaC measles virus induces potent RIG-I–dependent tumor clearance and immune memory Frederic Tangy, <i>Institut Pasteur Oncovita, France</i>	Structural Basis of 4G2-Induced Antibody-Dependent Enhancement in Flaviviruses Camilla Di Giulio, <i>Global Health Institute, EPFL, Switzerland</i>	Establishing a blood-stage Controlled Human Malaria Infection model in healthy Tanzanian adults with varying prior exposure to P. falciparum Omar Hassan, <i>Ifakara Health Institute, Tanzania</i> <i>Includes 5 minute Switchover Break</i>	
12:05-12:20	Therapeutic HBV vaccine efficacy through ancestral mismatched T cell epitopes Antonio Bertoletti, <i>Duke-NUS Medical School, Singapore</i>	Rational design of live-attenuated West Nile virus vaccines that are non-transmissible by vector mosquitoes Gorben Pijlman, <i>Wageningen University & Research, The Netherlands</i>	An Intranasal Hemagglutinin Protein Booster After Intramuscular mRNA Vaccination Enhances Mucosal Immunity and Confers Protection Against Influenza Virus in Ferrets Seokchan Park, <i>Icahn School of Medicine at Mount Sinai, USA</i> <i>Includes 5 minute Switchover Break</i>	
12:20-12:35	mRNA-Encoded HSV Monoclonal Antibody Based Immunotherapy Outperforms Acyclovir in a Murine Model of HSV-1 Encephalitis Sita Awasthi, <i>University of Pennsylvania, USA</i>	Novel dengue virus non-structural protein vaccine that can prevent disease exacerbation caused by existing vaccines Kyoko Tsukiyama-Kohara, <i>Kagoshima University, Japan</i>	Divergent innate and humoral immune responses to 4CMenB vaccination in transgender individuals receiving gender-affirming hormone therapy Anthony Willems, <i>Ghent University, Belgium</i> <i>Includes 5 minute Switchover Break</i>	
12:35-14:00	LUNCH			Room
13:00-14:00	NRC WORKSHOP			Room
14:00-15:30	POSTER SESSION 2			Room
14:30-15:30	ISV ANNUAL GENERAL MEETING			Room
15:30-16:00	COFFEE BREAK			Room
16:00-17:35	PLENARY SESSION 4: Systems Vaccinology <i>Session Chairs: TBC</i>			Room
16:00-16:25	Complexity from Simplicity: Using Systems Immunology to Define Conserved Innate Immune Mechanisms Mediating Diverse Effector Responses to Vaccines Jeffrey Tomalka, Emory University, USA			

16:25-16:50	<i>TITLE TBC</i> Fernando Ulloa-Montoya, Sanofi, France	
16:50-17:05	Induction of HIV broadly neutralizing antibodies by human vaccination Isabel Baken, Amsterdam UMC, The Netherlands	
17:05-17:20	Genome-guided identification and validation of novel T-cell vaccine targets for cross-species malaria protection Carla Proietti, The University of Queensland, Australia	
17:20-17:35	Novel DNA Delivery Method Using Lipid Nanoparticles Induces Durable Polyfunctional Immune Responses with Tier2 Neutralizing Antibody and Cytotoxic CD8 T Cells Barbara Felber, NCI/NIH, USA	
17:35-17:50	Immunological and transcriptomic profile of chimeric live-attenuated Zika vaccine linked to protection in non-human primates Ji Ma, <i>The First Affiliated Hospital (Southwest Hospital) of Army Medical University, People's Republic of China</i>	
18:30-22:00	GALA DINNER	Room

2026 ISV ANNUAL CONGRESS				
ORAL PROGRAM				
WEDNESDAY, 14 OCTOBER 2026				
08:00-08:30	WELCOME COFFEE			Room
08:30-09:00	KEYNOTE SPEAKER From Global Partnerships to Local Impact: Strengthening Vaccine Innovation <i>Laura Palomares, Instituto de Biotecnología UNAM</i>			Room
09:00-10:30	PLENARY SESSION 5: One Health and Pandemic Preparedness <i>Session Chairs: TBC</i>			Room
09:00-09:25	Active and Passive Mucosal Immunization Strategies for Improved Pandemic Preparedness <i>Matthew Miller, McMaster University, Canada</i>			
09:25-09:50	Antigenic evolution of H5 viruses and subtype-wide H5 vaccine development <i>Mathilde Richard, Erasmus MC, Netherlands</i>			
9:50-10:05	Safety of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in Tanzanian adults: an open-label, non-randomised phase 1 clinical trial <i>Latipha Mohamed, Ifakara Health Institute, Tanzani</i>			
10:05-10:20	Single-visit rabies vaccination with a simian adenovirus vector elicits durable neutralising antibody responses indicating likely protection for >2 years: mid-term results from the RAB002 phase Ib/II clinical trial <i>Alexander Douglas, University of Oxford, United Kingdom</i>			
10:20-10:35	Design, Development and Characterisation of Multivalent mRNA-LNP Vaccine Candidates for Mpox <i>Hapiloe Maranyane-Tshililo, Afrigen Biologics & Vaccines, South Africa</i>			
10:35-11:00	COFFEE BREAK			Room
11:00-12:35	CONCURRENT SESSION 7 <i>(Room)</i> Vaccine Confidence <i>Session Chairs: TBC</i>	CONCURRENT SESSION 8 <i>(Room)</i> Emerging Infections <i>Session Chairs: TBC</i>	CONCURRENT SESSION 9 <i>(Room)</i> Veterinary Vaccines <i>Session Chairs: TBC</i>	
11:00-11:25	The State of Vaccine Confidence in 2026 Emilie Karafillakis <i>London Institute for Tropical Medicine and Hygiene, United Kingdom</i>	TITLE TBC Camila Coehlo <i>Einstein Hospital Sao Paulo, Brazil</i>	TITLE TBC Fernando Rodríguez <i>IRTA-CReSA, Spain</i>	
11:25-11:50	Beyond Vaccine Hesitancy: Understanding and Rebuilding Trust in Vaccination in Complex Social Ecosystems Ève Dubé <i>Laval University, Canada</i>	TITLE TBC Raman Rao <i>Hilleman Labs, Singapore</i>	Gamma-SU: A serotype independent Strep. suis vaccine Tim Hirst <i>GPN Vaccines, Australia</i>	
11:50-12:05	Bridging the Mpox Vaccine Uptake Gap in Africa: Determinants of Acceptance and Hesitancy from a Systematic Review and Meta-Analysis Charles Ibeneme, <i>Texila America University Zambia Campus, Zambia</i>	Stabilized henipavirus fusion glycoproteins induce strong serum neutralizing antibody responses against of authentic virus and inform future vaccine design. Haye Nijhuis, <i>Amsterdam UMC, The Netherlands</i>	Selection and characterization of a contemporary respiratory syncytial virus subtype B strain for use in Controlled Human Infection Model (CHIM) studies Albert Osterhaus, <i>University of Veterinary Medicine, Germany</i>	
12:05-12:20	PANEL DISCUSSION	CD4+ T cell-mediated immunity protects from VSV-SUD lethal challenge in a mouse model of Sudan virus infection Lara Kelchtermans, <i>KU Leuven, Belgium</i>	Development of a vaccine against deadly elephant endotheliotropic herpesvirus Xander De Haan, <i>Utrecht University, The Netherlands</i>	

12:20-12:35	PANEL DISCUSSION	Characterization of the immune response to <i>Fusobacterium nucleatum</i> , an emerging pathogen associated with adverse pregnancy outcomes Tracy Lee, <i>BC Cancer Research Institute</i>	Late Breaker Abstract Speaker + Affiliation
12:35-14:00	LUNCH		Room
13:00-14:00	CAREER DEVELOPMENT WORKSHOP		Room
14:00-14:30	AWARD CEREMONY		Room
14:30-14:55	ISV PAPER OF THE YEAR A natural experiment on the effect of herpes zoster vaccination on dementia Pascal Gladsetzer, <i>Stanford University, USA</i>		Room
14:55-16:10	PLENARY SESSION 6: Human Challenge Studies <i>Session Chairs: TBC</i>		Room
14:55-15:20	TITLE TBC Joren Raymenants, <i>University of Antwerp, Belgium</i>		
15:20-15:45	TITLE TBC Christopher Chiu, <i>Imperial College London, United Kingdom</i>		
15:45-16:00	CLOSING SESSION & INTRODUCTION TO 2027 ISV CONGRESS		Room